October 19, 2015
Shire disappointed, wating lifitegrast, OPUS-3 study, data
“We were disappointed, but will soon have data from the Phase 3 study, OPUS 3,” said Flemming Ornskov, M.D., CEO, Shire.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: OPUS 3